(firstQuint)Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC).

 This is an open-label extension study of plecanatide in the treatment of patients with CIC who previously completed Synergy Protocols SP304-20210 and SP304203-00 (The CIC3 Study).

 The planned duration of each patient's study participation is up to 411 days, including up to 33 days of screening, 8 study visits over 52 weeks of treatment and a follow-up visit 2 weeks after the last dose of study drug.

.

 Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)@highlight

This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).

